Xin Lang Cai Jing·2025-07-29 03:55Group 1 - The Hong Kong Innovation Drug ETF (513120) has seen a strong increase of 3.37%, marking a four-day consecutive rise, with significant gains in constituent stocks such as Green Leaf Pharmaceutical (02186) up 8.50% and WuXi AppTec (02359) up 7.97% [1] - The ETF's trading volume was active, with a turnover of 31.99% and a total transaction value of 4.947 billion [1] - The ETF's latest scale reached 15.136 billion, a new high in nearly a year, ranking first among Hong Kong pharmaceutical ETFs [1] Group 2 - The CSI Hong Kong Innovation Drug Index (931787) closely tracks the performance of up to 50 listed companies involved in innovative drug research and development, with a significant weight of 92.5% in biopharmaceuticals and chemical pharmaceuticals [2] - As of June 30, 2025, the top ten weighted stocks in the index accounted for 67.94%, including companies like Innovent Biologics (01801) and WuXi Biologics (02269) [2] - WuXi AppTec reported a revenue of 20.799 billion, a year-on-year increase of 20.64%, with net profit rising by 101.92% to 8.56 billion [2] Group 3 - Heng Rui Medicine announced a licensing agreement with GSK for the global exclusive rights to the HRS-9821 project, receiving an upfront payment of 500 million and potential total payments of approximately 12 billion [3] - The total amount of overseas licensing transactions for innovative drugs in China increased by 26% in 2024, with over 2.5 billion in upfront payments in the first half of 2025 [3] - The Hong Kong Innovation Drug ETF supports T+0 trading, enhancing liquidity and capital efficiency for investors [3]